Company History - Zydus Pharmaceuticals

The Beginnings…
• India was heavily dependent after independence
• Self sufficiency in drugs and pharmaceuticals – need of the hour
• Mr. Ramanbhai B. Patel, quit his job as a lecturer at one of India’s
oldest pharmacy colleges, the L.M. College of Pharmacy to become an
entrepreneur
• He established Cadila Laboratories Ltd., in 1952.
•
1950s & 1960s : Cadila made a mark with innovative medicines and created
enduring brands
•
Livirubra – first of its kind in India to treat pernicious anemia
•
Introduced Isopar – a rational formulation of INH & PAS for the treatment of
tuberculosis.
•
Neuroxin-12 was the first of its kind, where incompatible neurotropics – B, B6,
B12 were made compatible in a vial.
•
Introduced Ampicillin in anhydrous form.
•
Received the National Award for import substitution. Develops the process
technology for the anti-diabetic drug Glibenclamide.
•
Dexona – 20 is launched for the first time in India to provide Dexamethasone
in concentrated form for the treatment of shocks.
•
1970s & 80s : Cadila became a benchmark for Quality and Excellence
•
Received the award for excellence in Quality from Indian Drug Manufacturers’
Association.
•
A full-fledged R&D centre set up with recognition from the Department of Science
and Technology, Govt. of India.
•
Answering the call to increase exports, the production unit of Cadila Exports was set
up at Kandla Free Trade Zone.
•
The unit was inaugurated by the former Prime Minister of India, Late Mrs. Indira
Gandhi.
•
Received the First Award from Chemexcil for it export performance consecutively for
two years from 1982-84 and the top award for export performance for the year 198586.
•
Entered the sphere of beauty care with a range of beauty care products.
1995 - 2000
Restructuring and establishing our business
and creating win-win alliances
1995-96
Zydus’ journey began with Rs 250 crs.
1995-96
Acquired Indo Pharma Pharmaceutical Works Ltd- the first acquisition
by the group
1995-96
Launched 23 new products in 1995, with first –in-India like Falcigo
1996-97
Registered the fastest growth among the top 80 Pharma companies in
India
1997-98
Entered into JV with BYK Gulden, a German pharma major to set up a
50:50 JV. (Byk was renamed as Altana Pharma and was later acquired
by Nycomed, which has now been acquired by Takeda).
1999-00
Project Disha led the way to TA focus in Domestic business
1999-00
Entered into Capital markets through - Initial Public offering (IPO)
1999-00
Entered into JV with Sarabhai for consolidating its position in Animal
Healthcare
2000-2006
Focusing on operational efficiencies, creating critical mass in
the domestic market and foraying into the international market
2000-01
Acquired Recon Healthcare. This move boosted the group’s strengths in southern markets
2000-01
Zydus Research Centre set up at Moraiya
2001-02
Acquired German Remedies; It was then the largest M&A in the Indian Pharmaceutical Sector.
2001-02
Acquired Aten and with it attained the top spot in CVS segment
2001-02
Acquired USFDA approved API plant – Banyan Chemicals
2002-03
DELTA & PRISM initiatives were introduced to institutionalize cost savings & optimal utilization of
internal resources
2002-03
Zyfine, a Fine Chemicals division was set up in March 2002 to cater to the need of the industries
which requires high purity products for chemical process.
2002-03
Zydus Pharmaceuticals USA Inc. is incorporated
2003-04
First international acquisition by acquiring Alpharma France [renamed as Zydus France]
2004-05
Filed our First IND in India for ZYH1
2005-06
Acquired 30.7% stake in Carnation Nutra Analogue Foods Ltd
2006 – 2012
Emergence as a global healthcare provider, robust NME
pipeline, thrust on operational efficiencies & continued
focus on domestic business
2006-07
Acquired Liva Healthcare & entered dermatology market
2006-07
Acquired Nippon Universal & with it entered the Japanese market
2007-08
Entered into branded generic market of Brazil with the acquisition of Quimica e
Farmaceutica Nikkho do Brasil Ltda
2007-08
Healthy Billion journey began with an aim to cross sales of $1bn by 2010-11
2007-08
Zydus entered research collaboration with Prolong
2008-09
Acquired Laboratorios Combix, Spain, Simayla Pharma of South Africa and Etna
Biotech of Italy
2008-09
SPEED – Initiative towards streamlining supply chain process – Creation of GDSO
2008-09
Entered segments of Nutraceutical, Rheumatology, COPD & Hospitals – Through
specialized divisions / TF
2009-10
Launched first formulation in India on Nano technology platform – Oxalgin Nanogel
2010-11
Entered into a strategic agreement with Abbott for commercializing branded
generics in emerging markets
2010-11
Launched Vaxiflu – S, India’s 1st H1N1 vaccine
2010-11
Zydus Wellness Ltd. (ZWL) which spearheads the Zydus group’s presence in the
consumer healthcare market listed as Asia’s 200 ‘Best under a Billion’ by Forbes.
2010-11
Zydus declared as the ‘Emerging Company of the Year’ by the Economic Times
Awards for Corporate Excellence 2010.
2010-11
Entered into a 50:50 JV with Bayer to set up a new marketing company
2010-11
Achieved the goal of the Healthy Billion – becoming a Billion Dollar company
2011-12
Entered into an agreement to acquire the assets of the US based pharmaceutical
company Nesher Pharmaceuticals Inc.
2011-12
The group’s formulations manufacturing plant at Baddi, Himachal Pradesh received
approval from the USFDA.
2011-12
Made a foray into the ophthalmology segment by setting up a speciality division,
Zydus Occucare.
2011-12
Acquired German company, Bremer Pharma GmbH, from ICICI Venture, to gain a
global footprint in the animal healthcare business.
2011-12
Acquired 100% stake in Biochem, one of the top 40 pharma companies in India
2011-12
Signed an agreement with Microbix Biosystems Inc., to market the Thrombolytic
drug, Urokinase in the North America
2012 and beyond
Emergence as a global healthcare group with operations
across 4 continents, robust NME pipeline, and a mission
to create healthier communities globally
13
2012-13
Beyond the Billion goal flagged off. The aim is post revenues of over $3bn by 2015
2012-13
VICA – the pillars to support the BTB aspiration launched. The four pillars stand for
Value Creation, Innovation, Collaboration and Accountability
2012-13
Launched PRISM 2, the cost optimisation programme which has identified savings
of over Rs. 200 crores spread across three waves
2012-13
Zydus Innovation Farm launched to plant, nurture and harvest ideas in the
organisation. Over 2000 ideas planted in the first 6 months
2012-13
Circles of Collaboration launched with over 50 Service Level Agreements signed to
facilitate cross functional efficiency
2012-13
VICA-BTB Value Days launched across the Zydus World to align organisational
priorities
2012-13
A total of over 114 new products launched during the year of which 31 were first in
India launches
2012-13
In the year 2012, 37 ANDAs were filed of which 12 have been approved taking the
cumulative to 170 filings and 75 approvals.
Our acquisition trail
Zydus Cadila Today: A global, mid-sized Pharma company
~60 years
$ 1 bn +
~6% of sales
Operational
experience
Global Revenues
Spent on R&D annually
20+ mfg. sites
~25% CAGR
300+ products
Producing >12
bn pills annually
In Sales and
Net Worth
(FY ‘06 – FY ‘11)
Registered annually
for US, EU, Japan and
emerging mkts.
15,000+ employees
Across the globe, with
>1050 for R&D
>35% CAGR
In Net Profits
(FY ‘06 – FY ‘11)
Among top 5
20 brands
Pharmaceutical
Companies in India
Among top 300
brands in India
11th largest
Generic co. In US in
terms of prescriptions
$ 3 bn +
Market Cap
8 NCE programmes
In pipeline, at various
stages of clinical trials
17 Biosimilars
In pipeline, apart from
2 novel biologics
650+ patents
Filed globally